BACKGROUND Cerebral embolization is a frequent complication after transcatheter aortic valve replacement (TAVR).
Although neurological complications
were identified early as a potentially major clinical issue (1) , recent data have indicated no increased risk of stroke for patients undergoing TAVR versus a surgical approach (2, 3) . Systematic magnetic resonance imaging (MRI) studies (4) (5) (6) (7) (8) have also shown that new cerebral emboli were observed in most patients within days after TAVR. Such silent events may accelerate cognitive decline over time (9, 10) .
With the possibility of extending TAVR to intermediate-risk patients with aortic stenosis using new TAVR devices (11), the incidence of neurological events must be reduced as much as possible.
Cerebral emboli may originate from several sources, such as material related to the manipulation of the aortic valve, and/or the aortic arch. A recent randomized study in patients undergoing TAVR demonstrated a reduction of cerebral emboli by the use of a protection device (8) . Nevertheless, the majority of patients even in the "embolic protected"
group still had evidence of new cerebral emboli.
A pharmacologic approach to prevent cerebral emboli during TAVR has not been tested. Previous studies have shown in the majority of cases that cerebral emboli are composed of thrombotic material (12, 13) . Furthermore, native aortic valve tissue is disrupted at the time of TAVR and contains very high levels of thrombin and tissue factor (14) . When performing both balloon valvuloplasty and TAVR, this tissue factor is exposed to the circulation, promoting coagulation. It is therefore important to investigate whether different procedural anticoagulation strategies have an effect on rates of cerebral embolization, and to identify any relationship between "silent emboli" as seen on MRI and clinical stroke (8) .
In the BRAVO (Effect of Bivalirudin on Aortic Valve
Intervention Outcomes)-3 randomized trial on TAVR procedural pharmacotherapy, bivalirudin was noninferior to heparin in terms of net adverse cardiovascular events within 30 months. There were no significant differences in overall major adverse cardiac/cerebrovascular or bleeding events; only the individual rate of periprocedure myocardial infarction was lower with bivalirudin (15) . A pre-specified nested MRI substudy was included in the BRAVO-3 trial (15, 16) . 
METHODS
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A U G U S T 9 , 2 0 1 6 : 5 8 9 -9 9 on a scale from 0% to 100%, with higher scores indicating greater surgical risk and a score of >20%
indicating very high risk (18) . Event rates were tested using the chi-square test. The primary data analysis was performed according to the intention-to-treat principle. The Kaplan-Meier method was used for the time-to-event analysis based on all available follow-up data and the log-rank test was used for the comparison. Multivariable Cox proportional hazards models, adjusting for baseline covariates, were conducted. Statistical analyses were performed using SAS software (version 9.2, SAS Institute, Cary, North Carolina).
RESULTS
Of the 69 patients of the BRAVO-3 MRI study, 33 were randomized to bivalirudin and 36 to UFH. Postprocedural MRI could not be performed in 9 patients (13%) (Figure 1 ). DW-MRI was performed 4.2 AE 3.9 days after TAVR.
Most of the baseline characteristics of the patients were well matched between the bivalirudin (n ¼ 29)
and heparin (n ¼ 31) groups ( ischemic attack are summarized in Table 3 . Table 2) . When analyzing embolization per TIA ¼ transient ischemic attack; other abbreviations as in Table 2 .
hemisphere, no difference in "anatomical brain dis- Subgroup analyses did not demonstrate any significant interaction relating to a differential effect between the 2 study treatments (Central illustration). Table 4 .
Predictors of new cerebral lesions are listed in
No deaths or myocardial infarctions were observed.
When compared with UFH, the use of bivalirudin was not associated with significant differences in major 
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had the highest rates of emboli (>80%) (5, 7, 8) , compared with rates of <65% in a study in which >80% of patients underwent MRI (6) ; in the present study, 87% of patients underwent post-procedural MRI (only 13% dropout rate).
A minority of patients with new embolic lesions after TAVR shows overt neurological deficits (3). However, the incidence of such deficits is variable, due to the clinical endpoint definition used and the lack of standardized post-procedural imaging and routine neurocognitive assessment. For overall embolic events, the total lesion volume is currently considered the most informative brain imaging measure, with excellent intrarater and inter-rater concordance for DW-MRI (21, 22) . Also, the BRAVO-3 MRI study measured the total volume of emboli (median:
45 mm 3 ), with no significant difference between bivalirudin and heparin groups. The median volume of the largest embolus per patient was 44.5 mm 3 , which is greater than the 35.5 mm 3 documented in the embolic protection arm of a recent randomized study (8) .
Regarding clinical neurological deficits, overt stroke is an extreme on a spectrum of possible adverse neuroembolic outcomes after TAVR. Over time, the occurrence of stroke after TAVR has declined to 1.7% to 3.4% (3, 11, 23) . In the present MRI study, the rate of overt stroke in the UFH group was elevated (6.5% at 48 h and 12.9% at 30 days) and may . ‡Estimated glomerular filtration rate of <15 ml/min/1.73 m 2 (end-stage renal disease). §Vitamin K antagonist, UFH, or low-molecular-weight heparin.
OR ¼ odds ratio; other abbreviations as in Tables 1 and 2 .
reflect the small sample size, as the overall stroke rates in the main BRAVO-3 study were 2.0% at 48 h and 3.1% at 30 days without any significant difference between bivalirudin versus heparin groups (15) .
Although stroke rates after TAVR are low, the high incidence of neuroembolic events remains to be addressed, as the occurrence of "silent" embolic lesions can lead to acceleration of cognitive decline (10, 24) . It is also very important to clarify the potential (Table 6) .
A transcranial Doppler study during TAVR demonstrated that most procedural embolic events occur during balloon valvuloplasty, manipulation of catheters across the aortic valve, and valve implantation (25) . The mechanical interactions between the transcatheter heart valve, the calcified native valve, and the aortic wall appear to play an important role. Balloon post-dilation of the valve prosthesis for treatment of significant paravalvular leaks, Values are n (%) unless otherwise indicated. *Whichever occurs first.
BARC ¼ Bleeding Academic Research Consortium; other abbreviations as in Tables 1 and 2 . repeated device implantation attempts, and valve prosthesis dislodgment/embolization are also associated with higher rates of neuroembolic events, mainly #24 h after TAVR (26) . Native aortic valve tissue is disrupted at the time of TAVR. It contains high levels of thrombin and tissue factor, which is exposed to the circulation during the procedure (14) . Therefore, the BRAVO-3 MRI study hypothesized that the use of the direct thrombin inhibitor bivalirudin would achieve predictable procedural anticoagulation and 
